|21st May 2020||Omar Khwaja||3,500||Open or private sale||$12.96||$45,360.00|
|3rd April 2020||Robert W. Hesslein||3,091||Open or private sale||$8.51||$26,304.41|
|10th February 2020||Omar Khwaja||30,000||Grant/award etc.||$0.00|
|10th February 2020||Andre Turenne||81,250||Grant/award etc.||$0.00|
|10th February 2020||Robert W. Hesslein||27,500||Grant/award etc.||$0.00|
|10th February 2020||Allison Dorval||27,500||Grant/award etc.||$0.00|
|21st January 2020||Matthew P. Ottmer||3,724||Open or private sale||$13.36||$49,752.64|
|21st January 2020||Andre Turenne||10,705||Open or private sale||$13.36||$143,018.80|
|21st January 2020||Allison Dorval||3,128||Open or private sale||$13.36||$41,790.08|
|20th May 2019||Omar Khwaja||30,000||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.